Thrombocytopenia - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 101 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Thrombocytopenia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Thrombocytopenia - Pipeline Review, H2 2014', provides an overview of the Thrombocytopenia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thrombocytopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocytopenia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Thrombocytopenia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Thrombocytopenia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Thrombocytopenia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Thrombocytopenia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Thrombocytopenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Thrombocytopenia Overview 9
Therapeutics Development 10
Pipeline Products for Thrombocytopenia - Overview 10
Pipeline Products for Thrombocytopenia - Comparative Analysis 11
Thrombocytopenia - Therapeutics under Development by Companies 12
Thrombocytopenia - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Thrombocytopenia - Products under Development by Companies 17
Thrombocytopenia - Companies Involved in Therapeutics Development 18
Shionogi & Co., Ltd. 18
GlaxoSmithKline plc 19
BioLineRx, Ltd. 20
Eisai Co., Ltd. 21
Octapharma AG 22
Bayer AG 23
Portola Pharmaceuticals, Inc. 24
Uni-Bio Science Group Ltd. 25
Cellerant Therapeutics, Inc. 26
Bolder Biotechnology, Inc. 27
ViroMed Co., Ltd. 28
aTyr Pharma, Inc. 29
Neumedicines Inc. 30
Tarix Pharmaceuticals LTD. 31
STATegics, Inc. 32
Prophylix Pharma AS 33
InvivoGen Therapeutics 34
Myelo Therapeutics GmbH 35
Thrombocytopenia - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
rivaroxaban - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
immune globulin (human) - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
VM-501 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
UNI-rhIL-11 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
NL-201 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
eltrombopag olamine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
lusutrombopag - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
avatrombopag - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
BBT-030 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
BBT-045 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
NMIL-121 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
PEG-VM501 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
TXA-302 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Tmax - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Gene Therapy for Chemotherapy-Induced Thrombocytopenia - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
BL-8040 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
STST-4 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
CLT-009 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
PRT-060318 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Myelo-001 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Human Platelet Antigen-1a Immunoglobulin - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Thrombocytopenia - Recent Pipeline Updates 76
Thrombocytopenia - Dormant Projects 92
Thrombocytopenia - Discontinued Products 93
Thrombocytopenia - Product Development Milestones 94
Featured News & Press Releases 94
Jun 13, 2014: Ligand Partner GSK Announces Results of Phase 3 PETIT2 Study of Eltrombopag(Promacta/Revolade) in Pediatric Patients with Chronic Immune Thrombocytopenia 94
Oct 31, 2013: Kyowa Hakko Kirin Announces Launch Of Nplate In Taiwan 94
Sep 24, 2013: Ligand Partner GSK Receives Marketing Authorization from the European Commission for Additional Revolade Indication as the First Approved Treatment for Chronic Hepatitis C-Associated Thrombocytopenia 95
Aug 05, 2013: BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia 95
Jul 26, 2013: Ligand Partner GlaxoSmithKline Receives Positive CHMP Opinion for REVOLADE in Thrombocytopenia Associated with Chronic Hepatitis C Infection 96
Apr 04, 2013: New therapeutic option for immunocompromised patients in Canada 97
Nov 19, 2012: GlaxoSmithKline's Promacta Receives FDA Approval For Treatment Of Thrombocytopenia 97
Oct 08, 2012: Cellerant Receives $1.6m SBIR Contract Funding To Develop CLT-009 For Treatment Of Thrombocytopenia 98
Aug 28, 2012: Bolder BioTechnology Announces Publication Of Data Demonstrating Utility Of Company's Long-Acting IL-11 Analog To Prevent Renal Ischemia Reperfusion Injury 99
Jul 25, 2012: Ligand Partner GlaxoSmithKline Announces Priority Review For Supplemental New Drug Application For Promacta 99
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 100
Contact Us 101
Disclaimer 101

List of Tables
Number of Products under Development for Thrombocytopenia, H2 2014 10
Number of Products under Development for Thrombocytopenia - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Thrombocytopenia - Pipeline by Shionogi & Co., Ltd., H2 2014 18
Thrombocytopenia - Pipeline by GlaxoSmithKline plc, H2 2014 19
Thrombocytopenia - Pipeline by BioLineRx, Ltd., H2 2014 20
Thrombocytopenia - Pipeline by Eisai Co., Ltd., H2 2014 21
Thrombocytopenia - Pipeline by Octapharma AG, H2 2014 22
Thrombocytopenia - Pipeline by Bayer AG, H2 2014 23
Thrombocytopenia - Pipeline by Portola Pharmaceuticals, Inc., H2 2014 24
Thrombocytopenia - Pipeline by Uni-Bio Science Group Ltd., H2 2014 25
Thrombocytopenia - Pipeline by Cellerant Therapeutics, Inc., H2 2014 26
Thrombocytopenia - Pipeline by Bolder Biotechnology, Inc., H2 2014 27
Thrombocytopenia - Pipeline by ViroMed Co., Ltd., H2 2014 28
Thrombocytopenia - Pipeline by aTyr Pharma, Inc., H2 2014 29
Thrombocytopenia - Pipeline by Neumedicines Inc., H2 2014 30
Thrombocytopenia - Pipeline by Tarix Pharmaceuticals LTD., H2 2014 31
Thrombocytopenia - Pipeline by STATegics, Inc., H2 2014 32
Thrombocytopenia - Pipeline by Prophylix Pharma AS, H2 2014 33
Thrombocytopenia - Pipeline by InvivoGen Therapeutics, H2 2014 34
Thrombocytopenia - Pipeline by Myelo Therapeutics GmbH, H2 2014 35
Assessment by Monotherapy Products, H2 2014 36
Number of Products by Stage and Target, H2 2014 38
Number of Products by Stage and Mechanism of Action, H2 2014 40
Number of Products by Stage and Route of Administration, H2 2014 42
Number of Products by Stage and Molecule Type, H2 2014 44
Thrombocytopenia Therapeutics - Recent Pipeline Updates, H2 2014 76
Thrombocytopenia - Dormant Projects, H2 2014 92
Thrombocytopenia - Discontinued Products, H2 2014 93